Results of Issue

RNS Number : 3972I

The MedicX Fund Limited

10 March 2010

 



For immediate release                                                                                                     10 March 2010

THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE REPUBLIC OF IRELAND, THE REPUBLIC OF SOUTH AFRICA, NEW ZEALAND OR JAPAN

MedicX Fund Limited

("MedicX Fund", "the Fund" or "the Company")

Results of Placing, Open Offer and Offer for Subscription and

Total Voting Rights

Results of Issue

The Board of Directors of MedicX Fund Limited, (LSE: MXF) (the "Company"), the specialist primary care infrastructure investor in modern purpose-built primary healthcare properties in the United Kingdom, is pleased to announce the results of its Placing, Open Offer and Offer for Subscription (together, the "Issue") of new ordinary shares (the "New Ordinary Shares") at an issue price of 72p per New Ordinary Share (the "Issue Price").

The Company has raised approximately £24.69 million pursuant to the Issue.  A total of 34,291,028 New Ordinary Shares will be issued at the Issue Price.

Applications were received for a total of 13,136,142 New Ordinary Shares under the Open Offer, of which 521,826 were applied for under the Excess Application Facility.  A further 44,000 New Ordinary Shares were applied for under the Offer for Subscription.  The balance of 21,110,886 New Ordinary Shares will be issued pursuant to the Placing.

David Staples, the Chairman of the Company, took up his entitlement to 10,000 New Ordinary Shares under the Open Offer.

Application has been made for the New Ordinary Shares to be admitted to the Official List of the UK Listing Authority and to trading on the main market for listed securities of the London Stock Exchange.  Dealings in the New Ordinary Shares are expected to commence on 12 March 2010.

The New Ordinary Shares, when issued and fully paid, will rank pari passu with the existing Ordinary Shares. 

Following Admission, the Company will have a market capitalisation (at the Issue Price) of £100.3 million.

Total Voting Rights

Following Admission, the total issued share capital of the Company will consist of 139,312,243 Ordinary Shares with voting rights.  This figure may be used by shareholders as the denominator for the calculation by which they will determine whether they are required to notify their interest in, or a change to their interest in, the Company under the FSA's Disclosure and Transparency Rules.

Terms defined in the prospectus published by the Company on 15 February 2010 shall have the same meanings in this announcement.

Further information on the Company can be found on the Company's website www.medicxfund.com.

For further information please contact:

MedicX Fund                                                                  [phone]

David Staples, Chairman

MedicX Group                                                                [phone]

Keith Maddin, Chairman

Mike Adams, Chief Executive Officer

Mark Osmond, Chief Financial Officer

Collins Stewart Europe Limited                                        [phone]

Andrew Zychowski/Lucy Lewis

Buchanan Communications                                              [phone]

Charles Ryland/Lisa Baderoon/Miranda Higham

Information on MedicX Fund Limited

MedicX Fund Limited ("MXF", the "Fund" or the "Company", or together with its subsidiaries, the "Group") is the specialist primary care infrastructure investor in modern, purpose-built primary healthcare properties in the United Kingdom, listed on the London Stock Exchange, with a portfolio comprising 51 properties.

The Investment Adviser to the Company is MedicX Adviser Ltd, which is authorised and regulated by the Financial Services Authority and is a subsidiary of the MedicX Group. The MedicX Group is a specialist investor, developer and manager of healthcare properties with 34 people operating across the UK.  

The Company's website address is www.medicxfund.com 

Important Information

This announcement is for information purposes only and does not constitute an offer of, or the solicitation of an offer to buy or subscribe for, any securities of the Company to any person in any jurisdiction and is not for release, publication or distribution in or into the United States, Japan, Canada, Australia, the Republic of South Africa, New Zealand or the Republic of Ireland. The New Ordinary Shares to be issued under the Open Offer, Offer for Subscription and the Placing have not been and will not be registered under the US Securities Act of 1933, as amended or under the applicable securities laws of Japan, Canada, Australia, the Republic of South Africa, New Zealand or the Republic of Ireland. Subject to certain exceptions, the New Ordinary Shares may not be offered sold or resold in the United States, Japan, Canada, Australia, the Republic of South Africa, New Zealand or the Republic of Ireland.

Collins Stewart Europe Limited, which is authorised and regulated in the United Kingdom by the Financial Services Authority, is acting as sponsor to MedicX Fund Limited and is acting for no-one else in connection with the Issue and the contents of this announcement, and will not be responsible to anyone other than the Company for providing the protections afforded to clients of Collins Stewart Europe Limited nor for providing advice in connection with the Issue and the contents of this announcement or any other matter referred to herein. Collins Stewart Europe Limited is not responsible for the contents of this announcement. This does not exclude or limit any responsibilities which Collins Stewart Europe Limited may have under the Financial Services and Markets Act 2000 (as amended) or the regulatory regime established thereunder.

 

END

 

 

ROIQBLFFBXFXBBE